CALGARY, Alberta--(BUSINESS WIRE)--Fero Industries, Inc. (OTCBB: FROI) (the “Company”), is pleased to disclose its growth strategy. FROI’s first acquisition target is Pyro Pharmaceuticals, Inc., a boutique developmental stage pharmaceutical company located in Irvine, CA. Pyro’s focus is on developing a new class of antibiotics to fight drug resistant bacteria, such as MRSA.
